Gene Therapy Approaches
DOI:
https://doi.org/10.48161/qaj.v1n1a35Abstract
Gene therapy can be described broadly as the transfer of genetic material to control a disease or at least to enhance a patient's clinical status. The transformation of viruses into genetic shuttles is one of the core principles of gene therapy, which will introduce the gene of interest into the target tissue and cells. To do this, safe strategies have been invented, using many viral and non-viral vector delivery. Two major methods have emerged: modification in vivo and modification ex vivo. For gene therapeutic approaches which are focused on lifelong expression of the therapeutic gene, retrovirus, adenovirus, adeno-associated viruses are acceptable. Non-viral vectors are much less successful than viral vectors, but because of their low immune responses and their broad therapeutic DNA ability, they have advantages. The addition of viral functions such as receptor-mediated uptake and nuclear translocation of DNA may eventually lead to the development of an artificial virus in order to improve the role of non-viral vectors. For human use in genetic conditions, cancers and acquired illnesses, gene transfer techniques have been allowed. The ideal delivery vehicle has not been identified, although the accessible vector systems are capable of transporting genes in vivo into cells. Therefore, only with great caution can the present viral vectors be used in human beings and further progress in the production of vectors is required. Current progresses in our understanding of gene therapy approaches and their delivery technology, as well as the victors used to deliver therapeutic genes, are the primary goals of this review. For that reason, a literature search on PubMed and Google Scholar was carried out using different keywords.
Downloads
References
M. Cavazzana-Calvo et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," (in eng), Science, vol. 288, no. 5466, pp. 669-72, Apr 28 2000, doi: 10.1126/science.288.5466.669.
M. Cavazzana-Calvo, S. Hacein-Bey, F. Yates, J. P. de Villartay, F. Le Deist, and A. Fischer, "Gene therapy of severe combined immunodeficiencies," (in eng), J Gene Med, vol. 3, no. 3, pp. 201-6, May-Jun 2001, doi: 10.1002/1521-2254(200105/06)3:3<201::aid-jgm195>3.0.co;2-z.
S. A. Rosenberg et al., "Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction," (in eng), N Engl J Med, vol. 323, no. 9, pp. 570-8, Aug 30 1990, doi: 10.1056/nejm199008303230904.
M. L. Edelstein, M. R. Abedi, J. Wixon, and R. M. Edelstein, "Gene therapy clinical trials worldwide 1989-2004-an overview," (in eng), J Gene Med, vol. 6, no. 6, pp. 597-602, Jun 2004, doi: 10.1002/jgm.619.
M. Mishra, "A review on gene therapy: History, vectors, technologies and application," WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 5, 01/26 2018, doi: 10.20959/wjpps201610-7891.
D. P. Wolf, P. A. Mitalipov, and S. M. Mitalipov, "Principles of and strategies for germ-line gene therapy," (in eng), Nat Med, vol. 25, no. 6, pp. 890-897, Jun 2019, doi: 10.1038/s41591-019-0473-8.
A. Bank, "Human somatic cell gene therapy," BioEssays, https://doi.org/10.1002/bies.950181210 vol. 18, no. 12, pp. 999-1007, 1996/12/01 1996, doi: https://doi.org/10.1002/bies.950181210.
S. Durai, M. Mani, K. Kandavelou, J. Wu, M. H. Porteus, and S. Chandrasegaran, "Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells," (in eng), Nucleic Acids Res, vol. 33, no. 18, pp. 5978-90, 2005, doi: 10.1093/nar/gki912.
Z. Peng, "Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers," (in eng), Hum Gene Ther, vol. 16, no. 9, pp. 1016-27, Sep 2005, doi: 10.1089/hum.2005.16.1016.
B. Sibbald, "Death but one unintended consequence of gene-therapy trial," in Cmaj, vol. 164, no. 11), 2001, p. 1612.
J. L. Santiago-Ortiz and D. V. Schaffer, "Adeno-associated virus (AAV) vectors in cancer gene therapy," (in eng), J Control Release, vol. 240, pp. 287-301, Oct 28 2016, doi: 10.1016/j.jconrel.2016.01.001.
W. Walther and U. Stein, "Viral vectors for gene transfer: a review of their use in the treatment of human diseases," (in eng), Drugs, vol. 60, no. 2, pp. 249-71, Aug 2000, doi: 10.2165/00003495-200060020-00002.
M. Hao, C. Huang, and N. Xia, "[The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy]," (in chi), Bing Du Xue Bao, vol. 32, no. 4, pp. 516-22, Jul 2016.
R. Gardlík, R. Pálffy, J. Hodosy, J. Lukács, J. Turna, and P. Celec, "Vectors and delivery systems in gene therapy," (in eng), Med Sci Monit, vol. 11, no. 4, pp. Ra110-21, Apr 2005.
T. G. Park, J. H. Jeong, and S. W. Kim, "Current status of polymeric gene delivery systems," (in eng), Adv Drug Deliv Rev, vol. 58, no. 4, pp. 467-86, Jul 7 2006, doi: 10.1016/j.addr.2006.03.007.
H. Yoshino, K. Hashizume, and E. Kobayashi, "Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume," (in eng), Gene Ther, vol. 13, no. 24, pp. 1696-702, Dec 2006, doi: 10.1038/sj.gt.3302833.
H. Yazawa et al., "Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors," (in eng), Cancer Gene Ther, vol. 13, no. 11, pp. 993-1001, Nov 2006, doi: 10.1038/sj.cgt.7700970.
M. Cemazar, M. Golzio, G. Sersa, M. P. Rols, and J. Teissié, "Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand?," (in eng), Curr Pharm Des, vol. 12, no. 29, pp. 3817-25, 2006, doi: 10.2174/138161206778559740.
J. A. Wolff and V. Budker, "The mechanism of naked DNA uptake and expression," (in eng), Adv Genet, vol. 54, pp. 3-20, 2005, doi: 10.1016/s0065-2660(05)54001-x.
M. Jafari, M. Soltani, S. Naahidi, D. N. Karunaratne, and P. Chen, "Nonviral approach for targeted nucleic acid delivery," (in eng), Curr Med Chem, vol. 19, no. 2, pp. 197-208, 2012, doi: 10.2174/092986712803414141.
E. G. Nabel and G. J. Nabel, "Direct gene transfer: basic studies and human therapies," (in eng), Thromb Haemost, vol. 70, no. 1, pp. 202-3, Jul 1 1993.
A. Sato, M. Takagi, A. Shimamoto, S. Kawakami, and M. Hashida, "Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice," (in eng), Biomaterials, vol. 28, no. 7, pp. 1434-42, Mar 2007, doi: 10.1016/j.biomaterials.2006.11.010.
L. T. Nguyen, K. Atobe, J. M. Barichello, T. Ishida, and H. Kiwada, "Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes," (in eng), Biol Pharm Bull, vol. 30, no. 4, pp. 751-7, Apr 2007, doi: 10.1248/bpb.30.751.
A. Rolland, "Gene medicines: the end of the beginning?," (in eng), Adv Drug Deliv Rev, vol. 57, no. 5, pp. 669-73, Apr 5 2005, doi: 10.1016/j.addr.2005.01.002.
T. Azzam and A. J. Domb, "Current developments in gene transfection agents," (in eng), Curr Drug Deliv, vol. 1, no. 2, pp. 165-93, Apr 2004, doi: 10.2174/1567201043479902.
M. A. Wolfert et al., "Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA," (in eng), Bioconjug Chem, vol. 10, no. 6, pp. 993-1004, Nov-Dec 1999, doi: 10.1021/bc990025r.
J. M. Benns, J. S. Choi, R. I. Mahato, J. S. Park, and S. W. Kim, "pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer," (in eng), Bioconjug Chem, vol. 11, no. 5, pp. 637-45, Sep-Oct 2000, doi: 10.1021/bc0000177.
I. Fajac et al., "Histidylated polylysine as a synthetic vector for gene transfer into immortalized cystic fibrosis airway surface and airway gland serous cells," (in eng), J Gene Med, vol. 2, no. 5, pp. 368-78, Sep-Oct 2000, doi: 10.1002/1521-2254(200009/10)2:5<368::aid-jgm118>3.0.co;2-f.
L. V. Kalia and A. E. Lang, "Parkinson's disease," (in eng), Lancet, vol. 386, no. 9996, pp. 896-912, Aug 29 2015, doi: 10.1016/s0140-6736(14)61393-3.
C. W. Olanow, M. B. Stern, and K. Sethi, "The scientific and clinical basis for the treatment of Parkinson disease (2009)," (in eng), Neurology, vol. 72, no. 21 Suppl 4, pp. S1-136, May 26 2009, doi: 10.1212/WNL.0b013e3181a1d44c.
A. M. Keeler, M. K. ElMallah, and T. R. Flotte, "Gene Therapy 2017: Progress and Future Directions," (in eng), Clin Transl Sci, vol. 10, no. 4, pp. 242-248, Jul 2017, doi: 10.1111/cts.12466.
I. Gabel and J. Moreno, "Genome Editing, Ethics, and Politics," (in eng), AMA J Ethics, vol. 21, no. 12, pp. E1105-1110, Dec 1 2019, doi: 10.1001/amajethics.2019.1105.
J. S. Smolen, D. Aletaha, and I. B. McInnes, "Rheumatoid arthritis," (in eng), Lancet, vol. 388, no. 10055, pp. 2023-2038, Oct 22 2016, doi: 10.1016/s0140-6736(16)30173-8.
S. Liu and K. Maeyama, "Gene Therapy for Rheumatoid Arthritis," (in eng), Crit Rev Immunol, vol. 36, no. 2, pp. 149-161, 2016, doi: 10.1615/CritRevImmunol.2016017062.
Y. Jiang et al., "A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores," (in eng), Arthritis Rheum, vol. 43, no. 5, pp. 1001-9, May 2000, doi: 10.1002/1529-0131(200005)43:5<1001::aid-anr7>3.0.co;2-p.
J. N. Gouze et al., "Gene therapy for rheumatoid arthritis," (in eng), Hand Surg, vol. 6, no. 2, pp. 211-9, Dec 2001, doi: 10.1142/s0218810401000709.
A. Nakajima et al., "Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis," (in eng), J Clin Invest, vol. 107, no. 10, pp. 1293-301, May 2001, doi: 10.1172/jci12037.
S. H. Kim, S. Kim, T. J. Oligino, and P. D. Robbins, "Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL," (in eng), Mol Ther, vol. 6, no. 5, pp. 584-90, Nov 2002.
N. Saidenberg-Kermanac'h et al., "Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis," (in eng), J Gene Med, vol. 5, no. 2, pp. 164-71, Feb 2003, doi: 10.1002/jgm.321.
G. A. R. Gonçalves and R. M. A. Paiva, "Gene therapy: advances, challenges and perspectives," (in eng por), Einstein (Sao Paulo), vol. 15, no. 3, pp. 369-375, Jul-Sep 2017, doi: 10.1590/s1679-45082017rb4024.
A. V. Levin, "Ethical considerations in gene therapy," (in eng), Ophthalmic Genet, vol. 37, no. 3, pp. 249-51, Sep 2016, doi: 10.3109/13816810.2015.1121501.
C. Brakebusch, "CRISPR Genome Editing: How to Make a Fantastic Method Even Better," Cells, vol. 10, no. 2, 2021, doi: 10.3390/cells10020408.
P. Sledzinski, M. Nowaczyk, and M. Olejniczak, "Computational Tools and Resources Supporting CRISPR-Cas Experiments," (in eng), Cells, vol. 9, no. 5, May 22 2020, doi: 10.3390/cells9051288.
T. Gaj, C. A. Gersbach, and C. F. Barbas, 3rd, "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering," (in eng), Trends Biotechnol, vol. 31, no. 7, pp. 397-405, Jul 2013, doi: 10.1016/j.tibtech.2013.04.004.
S. Patil, I. A. Al-Zoubi, P. H. Raghuram, N. Misra, N. Yadav, and M. Alam, "Gene therapy: A comprehensive review," International Medical Journal, vol. 25, pp. 361-364, 12/01 2018.
S. Ginn and I. Alexander, "Gene Therapy," 2016, pp. 1-19.
M. Collins and A. Thrasher, "Gene therapy: Progress and predictions," Proceedings. Biological sciences / The Royal Society, vol. 282, 12/24 2015, doi: 10.1098/rspb.2014.3003.
I. Gabel and J. Moreno, "Genome Editing, Ethics, and Politics," (in eng), AMA J Ethics, vol. 21, no. 12, pp. E1105-1110, Dec 1 2019, doi: 10.1001/amajethics.2019.1105.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Qubahan Academic Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
